Document is current
Any future updates will be listed below
-
Authors
Faconti, Luca https://orcid.org/0000-0002-1066-6899
George, Jacob
Partridge, Sarah
Maniero, Carmen
Sathyanarayanan, Abilash https://orcid.org/0000-0002-8319-6744
Kulkarni, Spoorthy
Kapil, Vikas
Petrosino, Alfredo https://orcid.org/0009-0003-0986-0621
Lewis, Philip https://orcid.org/0000-0002-7903-390X
McCormack, Terry https://orcid.org/0000-0002-9688-6031
Poulter, Neil R. https://orcid.org/0000-0002-6292-997X
Heagerty, Anthony
Wilkinson, Ian B. https://orcid.org/0000-0001-6598-9399
- License Information
-
More Information
Article History
Received: 11 November 2024
Revised: 15 November 2024
Accepted: 27 November 2024
First Online: 9 December 2024
Competing interests
: Professor Adrian J.B. Brady has received honoraria from Daiichi-Sankyo, Amgen, Sanofi-Aventis, Bayer, MSD, and Novartis. Professor Phil Chowienczyk has an interest in Centron Diagnostics, a company that has produced technology for blood pressure measurement. Professor Jacob George has received grants and travel funding from Astra Zeneca, Novartis and Daiichi Sankyo, is on Advisory Boards for AstraZeneca, Menarini and Novartis, consulting fees from Roche and PwC and is a Principal Investigator for studies funded by AstraZeneca, Alnylam, Novartis, Esperion. Dr Pankaj Gupta has received research grants, lecture honoraria and funding for conference attendance from Sanofi-Aventis and Amgen, and consulting fees from Ionis Pharmaceuticals. Professor Anthony Heagerty has received lecture honoraria from Servier. Dr Spoorthy Kulkarni is a PhD student at the University of Cambridge funded by AstraZeneca and has attended scientific advisory boards for Viatris. Professor Terry McCormack has received lecture honoraria and/or consultation fees from AstraZeneca, Daichi-Sankyo, and Medtronic. He is a co-investigator in the Alnylam study Kardia 3. Professor Neil R Poulter has received lecture honoraria and/or consultation fees from several pharmaceutical companies that manufacture blood pressure lowering agents including AstraZeneca, Eva Pharma, Lri Therapharma, Napi, Pfizer, Servier and Sanofi-Aventis. Professor Ian B Wilkinson has received research grants from AstraZeneca, GSK and scientific advisory board consultation fees for Viatris, Astra Zeneca and Roche. Dr Luca Faconti, Dr Carmen Maniero, Dr Vikas Kapil, Dr Philip Lewis, Ms Michaela Nuttall, Mr Sam Olden, Dr Sarah Partridge, Dr Alfredo Petrosino, Dr Abilash Sathyanarayanan, Professor Peter Sever, Dr Wayne Sunman and Dr Helen Warren have no competing interests to declare for this manuscript.
